Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. granted options to purchase 170,000 shares of common stock to newly hired employees. The options have an exercise price of $2.59 per share, based on the closing trading price on the grant date. The grants were made under the 2016 Employment Commencement Incentive Plan.
02/23/2024 - 05:33 PM
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59 , the closing trading price on the grant date. One Executive Vice President level executive was granted an option to purchase 150,000 shares; and two additional non-officer employees were granted options to purchase an aggregate of 20,000 shares.
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Coherus Contact Information IR@coherus.com
What is the total number of shares granted to the newly hired employees by Coherus BioSciences, Inc.?
Coherus BioSciences, Inc. granted options to purchase an aggregate of 170,000 shares of common stock to three newly hired employees.
What is the exercise price per share for the granted options by Coherus BioSciences, Inc.?
The exercise price per share for the granted options by Coherus BioSciences, Inc. is $2.59, based on the closing trading price on the grant date.
Under which plan were the stock options granted by Coherus BioSciences, Inc.?
The stock options were granted under the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan.
CHRS Rankings
#5124 Ranked by Stock Gains
CHRS Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Redwood City
About CHRS
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
